Home > Publications > Peer-Reviewed Publications

Peer-Reviewed Publications

Chahal, M. et al. Personalized Oncogenomic Analysis of Metastatic Adenoid Cystic Carcinoma: Using Whole Genome Sequencing to Inform Clinical Decision Making. Cold Spring Harb Mol Case Stud. Accepted for publication, February 2018.
Ronsley, R. et al. Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma. Cold Spring Harb Mol Case Stud. Accepted for publication, February 2018.
Owen, D. et al. Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases. Cold Spring Harb Mol Case Stud. 08 February 2018. E-pub ahead of print.
Zhao, E et al. A Homologous Recombination Deficiency Signature Predicts Response to Platinum-Based Therapy. Clinical Cancer Research. Volume 23, Issue 24, 14 December 2017. Page 7521-7530
Jones, MR. et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Annals of Oncology, Volume 28, Issue 12, 1 December 2017, Pages 3092–3097
Wong, H. et al. Molecular characterisation of metastatic pancreatic neuroendocrine tumours (PNETs) using whole genome and transcriptome sequencing. Cold Spring Harb Mol Case Stud. 2017 Nov 1. pii: mcs.a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.
Grewal, J. et al. Detection and Genomic Characterization of a mammary-like adenocarcinoma. Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a002170. doi: 10.1101/mcs.a002170.
Chooback, N. et al. Carcinoma ex pleomorphic adenoma: Case report and options for systemic therapy. Current Oncology. 2017 Jun 27; 24(3). pii: co.24.3588. doi: 10.3747/co.24.3588.
Chow-White, P. et al. Knowledge, attitudes, and values amongphysicians working with clinical genomics:a survey of medical oncologists. Hum Resour Health. 2017 Jun 27;15(1):42. doi: 10.1186/s12960-017-0218-z.
Thibodeau, M. L. et al. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. Cold Spring Harb Mol Case Stud 2017 May 16. pii: mcs.a001628. doi: 10.1101/mcs.a001628
Weymann, D. et al. The cost and cost-trajectory of whole-genome analysis to guide treatment of patients with advanced cancer. Mol Genet Genomic Med. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281
Sheffield, B. S. et al. Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. Curr Oncol. 2016 Dec; 23(6), e571-e575. doi:10.3747/co.23.3165.
Laskin, J. et al. Clinicians identify high need to increase their genomic literacy to applied cancer genomics. Ann Oncol. 2016; 27 (suppl_6): 1379P. doi: 10.1093/annonc/mdw387.16
Sheffield, B. S. et al. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. J Histochem Cytochem 2016 Oct;64(10):587-600. doi: 10.1369/00221554 
Alassiri AH. et al. ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors. Am J Surg Pathol. 2016 Aug: 40(80):1051-61
Jones, M. R. et al. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology27, 801-806, doi:10.1093/annonc/mdw060 (2016).
Parker JD, et al. Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing. Cold Spring Harb Mol Case Stud. 2016 Mar 2.
Laskin J, Jones S, Aparicio S, et al. Lessons learned from the application of whole genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud. 1: a000570. 2015 Oct 27. doi:10.1371/journal.pone.0119689.
Bose, P. et al. Integrative genomic analysis of ghost cell odontogenic carcinoma. Oral Oncol. 2015 Sep 51(9): e71-e75. doi.org/10.1016/j.oraloncology.2015.06.013
Sheffield BS, Tinker AV, Shen Y, et al. Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome Sequencing. Deb S, ed. PLoS ONE. 2015;10(3):e0119689.
Jamshidi, F. et al. Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor. Oncologist. 2014 June; 19(6): 623-630. doi: 10.1634/theoncologist.2013-0390
Jones SJ, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 11(8):R82 (2010).